Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study

In recent years the use of immunomodulating therapy to treat various cancers has been on the rise. Three checkpoint inhibitors have been approved by the Food and Drug Administration (ipilimumab, pembrolizumab and nivolumab). The use of these drugs comes with serious adverse events related to excessi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical medicine research 2019, Vol.11 (4), p.225-236
Hauptverfasser:	Bajwa, Ravneet, Cheema, Anmol, Khan, Taimoor, Amirpour, Alireza, Paul, Anju, Chaughtai, Saira, Patel, Shrinil, Patel, Tejas, Bramson, Joshua, Gupta, Varsha, Levitt, Michael, Asif, Arif, Hossain, Mohammad A
Format:	Artikel
Sprache:	eng
Schlagworte:	Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!